SCHEMBL3028183

SCHEMBL3028183

CN(C)C(C)(C)CC(c1ccc(-c2cn[nH]c2)cc1)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT2 P31751 7/20 0.48
AKT1 P31749 10/20 0.46
PRKCD Q05655 2/20 0.46
PRKD3 O94806 1/20 0.46
PRKCG P05129 1/20 0.46
PRKCB P05771 1/20 0.46
BRAF P15056 1/20 0.46
PRKCA P17252 1/20 0.46
PRKCH P24723 1/20 0.46
PRKCI P41743 1/20 0.46
PRKCE Q02156 1/20 0.46
PRKCQ Q04759 1/20 0.46
PRKCZ Q05513 1/20 0.46
PRKD1 Q15139 1/20 0.46
ROCK2 O75116 5/20 0.36
PRKACA P17612 2/20 0.36
AKT3 Q9Y243 2/20 0.36
RPS6KA5 O75582 1/20 0.36
RPS6KA4 O75676 1/20 0.36
LATS1 O95835 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1978909 0.79 AKT2 (0.75) AKT2AKT1PRKCDPRKD3PRKCG
SCHEMBL3029663 0.79 AKT2 (0.47) AKT2AKT1PRKCDPRKD3PRKCG
SCHEMBL3030119 0.77 AKT2 (0.60) AKT2AKT1PRKCDPRKD3PRKCG
SCHEMBL1978674 0.77 AKT2 (0.60) AKT2AKT1PRKCDPRKD3PRKCG
SCHEMBL3019631 0.76 AKT2 (0.52) AKT2AKT1PRKCDPRKD3PRKCG
SCHEMBL13214515 0.76 AKT2 (0.52) AKT2AKT1PRKCDPRKD3PRKCG
SCHEMBL3019509 0.74 AKT2 (0.53) AKT2AKT1ROCK2ROCK1
SCHEMBL1978776 0.74 AKT2 (0.53) AKT2AKT1ROCK2ROCK1
SCHEMBL17494104 0.72 AHR (0.56) AKT2AKT1PRKCDPRKD3PRKCG
SCHEMBL13214849 0.72 AKT2 (0.47) AKT2AKT1ROCK2RPS6KB1ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100210617-A1 Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors ASTEX THERAPEUTICS LIMITED (GB) 2010-08-19 US disclosed
US-20100210617-A1 Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors ASTEX THERAPEUTICS LIMITED (GB) 2010-08-19 US disclosed
US-20100210617-A1 Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors ASTEX THERAPEUTICS LIMITED (GB) 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210617-A1 Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors ERBB2, ABL1, GRK2 AKT2 88/4885AKT1 73/4885PRKCD 620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.